Copiktra (duvelisib)

NOW APPROVED

The FIRST AND ONLY oral dual PI3K-δ and PI3K-γ inhibitor that targets malignant B cells and the tumor microenvironment.1,2

COPIKTRA is a kinase inhibitor indicated for the treatment of adult patients with1:

Relapsed or refractory CLL or SLL after at least 2 prior therapies

Relapsed or refractory FL after at least 2 prior systemic therapies
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

CLL, chronic lymphocytic leukemia; FL, follicular lymphoma; PI3K, phosphoinositide 3-kinase; SLL, small lymphocytic lymphoma.

Subscribe here to receive further information about COPIKTRA and other products and services offered by Verastem Oncology.

* required
Please complete all of the required fields to subscribe.
BY CLICKING SUBSCRIBE, I understand and agree to the Verastem Oncology Terms of Use and Privacy Policy.
I also agree to receive future communications from Verastem Oncology.
* required
Please complete all of the required fields to subscribe.